JP2022530824A5 - - Google Patents

Info

Publication number
JP2022530824A5
JP2022530824A5 JP2021564730A JP2021564730A JP2022530824A5 JP 2022530824 A5 JP2022530824 A5 JP 2022530824A5 JP 2021564730 A JP2021564730 A JP 2021564730A JP 2021564730 A JP2021564730 A JP 2021564730A JP 2022530824 A5 JP2022530824 A5 JP 2022530824A5
Authority
JP
Japan
Prior art keywords
sequence
expression cassette
raav
composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530824A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/030493 external-priority patent/WO2020223362A1/en
Publication of JP2022530824A publication Critical patent/JP2022530824A/ja
Publication of JP2022530824A5 publication Critical patent/JP2022530824A5/ja
Pending legal-status Critical Current

Links

JP2021564730A 2019-04-30 2020-04-29 ポンペ病の治療のために有用な組成物 Pending JP2022530824A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962840911P 2019-04-30 2019-04-30
US62/840,911 2019-04-30
US201962913401P 2019-10-10 2019-10-10
US62/913,401 2019-10-10
PCT/US2020/030493 WO2020223362A1 (en) 2019-04-30 2020-04-29 Compositions useful for treatment of pompe disease

Publications (2)

Publication Number Publication Date
JP2022530824A JP2022530824A (ja) 2022-07-01
JP2022530824A5 true JP2022530824A5 (cg-RX-API-DMAC7.html) 2023-05-08

Family

ID=73029176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564730A Pending JP2022530824A (ja) 2019-04-30 2020-04-29 ポンペ病の治療のために有用な組成物
JP2021565001A Active JP7585233B2 (ja) 2019-04-30 2020-04-29 ポンペ病の治療のために有用な組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021565001A Active JP7585233B2 (ja) 2019-04-30 2020-04-29 ポンペ病の治療のために有用な組成物

Country Status (16)

Country Link
US (3) US20220193261A1 (cg-RX-API-DMAC7.html)
EP (2) EP3963063A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022530824A (cg-RX-API-DMAC7.html)
KR (2) KR20220008280A (cg-RX-API-DMAC7.html)
CN (2) CN114127275A (cg-RX-API-DMAC7.html)
AU (2) AU2020266829A1 (cg-RX-API-DMAC7.html)
BR (2) BR112021021792A2 (cg-RX-API-DMAC7.html)
CA (2) CA3134485A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021002754A1 (cg-RX-API-DMAC7.html)
CO (2) CO2021016200A2 (cg-RX-API-DMAC7.html)
IL (2) IL287522A (cg-RX-API-DMAC7.html)
MX (2) MX2021013365A (cg-RX-API-DMAC7.html)
PH (2) PH12021552638A1 (cg-RX-API-DMAC7.html)
SG (2) SG11202111380VA (cg-RX-API-DMAC7.html)
TW (1) TW202100541A (cg-RX-API-DMAC7.html)
WO (2) WO2020223362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
JP2022552254A (ja) * 2019-10-10 2022-12-15 アミカス セラピューティックス インコーポレイテッド バリアントigf2構築体
EP4149519A4 (en) * 2020-05-14 2024-06-12 The Trustees of The University of Pennsylvania COMPOSITIONS FOR THE TREATMENT OF POMPE DISEASE
CA3183153A1 (en) 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
AU2022388800A1 (en) * 2021-11-12 2024-06-27 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of mucopolysaccharidosis iiia
NL2031676B1 (en) * 2022-04-22 2023-11-07 Univ Erasmus Med Ct Rotterdam Gene therapy for Pompe Disease
WO2024003687A1 (en) * 2022-06-28 2024-01-04 Pfizer Inc. Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
US20260216373A1 (en) * 2023-01-13 2026-07-30 Amicus Therapeutics, Inc. Gene Therapy Constructs for the Treatment of Pompe Disease
CN116693633B (zh) * 2023-02-21 2023-12-22 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2025171163A1 (en) * 2024-02-06 2025-08-14 Duke University Compositions for and methods of treating lysosomal storage diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1587923E (pt) * 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
AU2007322123A1 (en) * 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
WO2009137721A2 (en) * 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
EP2628803A3 (en) 2009-02-25 2014-01-01 Cepheid Methods of detecting lung cancer
US8785168B2 (en) * 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
HRP20181315T1 (hr) 2010-11-22 2018-10-19 Amicus Therapeutics, Inc. Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
WO2012070014A2 (en) * 2010-11-26 2012-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells
GB201103062D0 (en) * 2011-02-22 2011-04-06 Isis Innovation Method
LT2714752T (lt) * 2011-05-27 2018-03-12 Amicus Therapeutics, Inc. Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui
WO2013013019A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Lysosomal polypeptides, methods of making and using
CA2947466A1 (en) * 2014-05-01 2015-11-05 University Of Washington In vivo gene engineering with adenoviral vectors
AU2016366549B2 (en) * 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
KR102618519B1 (ko) * 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
EP3293260A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
KR102617502B1 (ko) * 2016-09-12 2023-12-26 제네똥 산-알파 글루코시다제 변이체 및 이의 용도
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
WO2018178067A1 (en) * 2017-03-27 2018-10-04 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
JP2018198611A (ja) 2018-08-03 2018-12-20 ウニベルシダッド アウトノマ デ バルセロナ 脂肪組織に形質導入するのに有用なアデノ随伴ウイルスベクター

Similar Documents

Publication Publication Date Title
JP7707261B2 (ja) 筋疾患の治療のための改変aavカプシドポリペプチド
JP2022530833A5 (cg-RX-API-DMAC7.html)
JP7776477B2 (ja) 転写調節要素及びその使用
KR102526711B1 (ko) 고효율 게놈 편집을 위한 아데노-관련 바이러스 벡터 변이체 및 이의 방법
JP3487597B2 (ja) 筋細胞内での発現のためのウイルス性組換え型ベクター
US6033885A (en) Integrative recombinant adenoviruses, preparation thereof and therapeutical uses thereof
ES2264123T3 (es) Adenovirus recombinantes defectivos para la terapia genica de tumores.
JP2022517174A5 (cg-RX-API-DMAC7.html)
JP2023526310A5 (cg-RX-API-DMAC7.html)
JP2022531861A5 (cg-RX-API-DMAC7.html)
KR20230084542A (ko) 플라코필린 2 유전자 치료 방법 및 조성물
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP2022553406A5 (cg-RX-API-DMAC7.html)
WO2023035687A1 (zh) 用于治疗庞贝氏病的基因治疗构建体、药物组合物和方法
EP4509606A1 (en) Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof
JP2002533359A (ja) 組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入
WO1999061034A1 (en) Improved vectors
JP2024514110A (ja) 不整脈原性右心室心筋症に対する遺伝子療法
US20030035794A1 (en) Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders
WO2021230385A1 (en) Method for treating muscular dystrophy by targeting utrophin gene
US20170065685A1 (en) Serca2 therapeutic compositions and methods of use
JP2022554141A (ja) 糖原病を治療するための組成物及び方法
CN112041437A (zh) 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
CN107073078A (zh) 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物
TW202337476A (zh) 用於與肌肉萎縮蛋白有關之心肌病之基因療法組合物及治療